Active not recruitingPHASE2INTERVENTIONAL

Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

This study, called ATLANTA, is for men newly diagnosed with prostate cancer that has spread (metastatic prostate cancer). It's a Phase II trial, meaning it's still in the earlier stages of research. Doctors want to see if adding treatments directly to the prostate gland, and sometimes to other areas where the cancer has spread, can improve how long patients live or how well they manage their cancer, compared to just receiving the standard treatments. These additional treatments might include surgery, radiotherapy, or less invasive procedures. The study aims to understand if these new approaches could be better options for patients in the future.

At a glance

Status

Active not recruiting

Phase

PHASE2

Sponsor

Imperial College London

Enrolment target

433

Start

10 Apr 2019

Estimated completion

31 Jan 2027

Prostate Cancer Metastatic Prostate Cancer

What is this study about?

When prostate cancer spreads to other parts of the body, it's called metastatic prostate cancer. Standard treatment usually involves medicines that work throughout the body to control the cancer. However, doctors are now exploring if treating the original tumour in the prostate, and other specific areas where the cancer has spread, in addition to these standard medicines, could lead to better results for patients.

This study, called ATLANTA, aims to find out if these additional treatments make a difference. It's designed to compare three groups of men: one group will receive only the standard treatments, and the other two groups will receive standard treatments plus extra procedures targeting the prostate itself. These extra procedures could be surgery (prostatectomy), radiotherapy (using radiation to kill cancer cells), or a less invasive method to destroy the tumour.

The main goal is to see if men who have these extra treatments live longer or have better control over their cancer. This research is important because it could help doctors understand if there are better ways to treat metastatic prostate cancer in the future, potentially improving the lives of many men.

Key takeaways

The study explores adding direct treatments to the prostate for men with spreading prostate cancer.
It compares standard care with standard care plus extra treatment to the prostate and sometimes other areas.
Treatments include surgery, radiotherapy, or less invasive methods.
It's an early-stage study (Phase II) aiming to improve future treatments.
Participation involves being randomly assigned to a treatment group and long-term monitoring.

Who may be eligible?

This study is looking for men who have recently been diagnosed with prostate cancer that has spread to other parts of the body. You would need to have received your prostate cancer diagnosis within the last six months to be considered.

To join, you must be well enough to have both the standard cancer treatments and the extra treatments being tested in the study, such as surgery or radiotherapy to your prostate. This means a doctor needs to confirm you are fit for these procedures. You will also need to have had certain scans to confirm the cancer has spread and to get a clear picture of your prostate.

There are also some reasons why you might not be able to join. For example, if you've already had long-term hormone therapy or chemotherapy for your prostate cancer (unless it was for a short time recently), or if you haven't had the necessary scans to confirm your cancer has spread.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Have you been diagnosed with prostate cancer that has spread in the last 6 months?
Are you well enough for standard cancer treatments AND potentially surgery/radiotherapy to your prostate?
Have you had the necessary scans (like CT, bone scan, prostate MRI) to confirm the spread of cancer?
Have you NOT had long-term hormone therapy or chemotherapy for your prostate cancer previously (unless very recently)?
Are you a male, aged 18 or older?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you'll be randomly assigned to one of three groups. This means a computer will decide which treatment plan you follow, like flipping a coin, so it's fair. One group will receive the standard care for metastatic prostate cancer as decided by your doctor. The other two groups will receive this standard care plus additional treatments targeting your prostate or other specific areas where the cancer has spread. These additional treatments could include surgery, radiotherapy, or a less invasive procedure.

The study aims to follow participants for a long time to see the effects of these treatments. You will have regular appointments, scans, and blood tests to monitor your health and how the treatment is working. The exact number of visits and tests will depend on which treatment group you are in and what your doctors recommend, but the study team will explain everything in detail if you are eligible.

Potential risks and benefits

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is that you might receive a new combination of treatments that could be more effective than standard care alone, potentially leading to better control of your cancer or a longer life. However, there's no guarantee that the new treatments will work better, and they might have side effects that standard treatments don't. The additional treatments like surgery or radiotherapy also carry their own known risks, such as infection, bleeding, or other complications. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (21)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Wirral University Teaching Hospital, Wirral University Teaching Hospital NHS Foundation Trust
Verified postcode
Birkenhead, United Kingdom
Glan Clwyd Hospital
Verified postcode
Bodelwyddan, United Kingdom
Darent Valley Hospital
Verified postcode
Dartford, United Kingdom
Royal Devon and Exeter NHS Trust
Verified postcode
Exeter, United Kingdom
Buckinghamshire Healthcare NHS Trust
Verified postcode
High Wycombe, United Kingdom
West Middlesex University Hospital
Verified postcode
Isleworth, United Kingdom
Queen Elizabeth Hospital, Kings Lynn
Verified postcode
Kings Lynn, United Kingdom
Chelsea and Westminster Hospital
Verified postcode
London, United Kingdom
The Royal Marsden NHS Foundation Trust, Chelsea Research Centre
Verified postcode
London, United Kingdom
Imperial College Healthcare NHS Trust
Verified postcode
London, United Kingdom
North Middlesex University Hospital
Verified postcode
London, United Kingdom
Northwick Park, London North West Healthcare NHS Trust
Verified postcode
London, United Kingdom

Common questions

What is 'metastatic prostate cancer'?

It means the prostate cancer has spread from the prostate gland to other parts of your body.

What is 'Standard of Care' treatment?

This is the usual, widely accepted treatment for your condition, which your doctor would typically recommend.

What is a 'Phase II' study?

It's an earlier stage of research where doctors are still primarily checking if a new treatment is safe and effective enough to warrant further larger studies.

Will I get to choose my treatment?

No, if you join, you'll be randomly assigned to one of the treatment groups, like drawing lots, to ensure the study is fair.

How long will I be in the study?

The study involves long-term follow-up to see how treatments affect patients over time, but your individual participation will be discussed with you.